Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
CareerViewXR Honored for Shaping America’s Future Workforce
-
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
-
Correction: Prepayments (CK93) - Nykredit Realkredit A/S
-
Bitcoin Bancorp to Present at NIBA’s 152nd Investment Conference in Fort Lauderdale Florida on March 11-12
-
Nayax Reports Fourth Quarter and Full Year 2025 Results
-
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis
-
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
-
VitalHub Announces Novari Health AI-Enhanced Referral Management Deployment
-
SL Green Reaches 100% Leased at the Transformative One Madison Avenue, Projects Record-Breaking First Quarter Office Leasing Across Portfolio
-
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
-
Trex Introduces Fire-Resistant Outdoor Decking
-
SPARC AI Ready to Deploy Overwatch to Ukraine
-
Calisa Acquisition Corp Announces Entering into Merger Agreement with GoodVision AI Inc
-
Green Circle Decarbonize Technology Limited Issues Statement Regarding Unusual Market Activity
-
Korro Announces Oversubscribed $85 Million Private Placement
-
Habit Makes a Splash for National Ranch Day with Free, Limited-Edition Ranch Floatie
-
FTI Consulting Elects Angela Nam as Chief Financial Officer
-
Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
-
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset
-
FuelCell Energy Delivers Strong Q1’26 Revenue Growth vs Q1’25; Advances Data Center Power Strategy
-
No. 6/2026 - CeMat A/S acquires right of perpetual usufruct to land plot in Bielany, Warsaw
-
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
-
Alexander’s to Sell Rego Park I for Net Proceeds of $202 Million
-
Share buy-back program
-
Movellus Advanced Clocking IP Selected for QuickLogic’s Strategic Radiation Hardened FPGA Program
-
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
-
Ubitium tapes out universal processor to end embedded computing complexity crisis
-
Panda Express® Brings Back Its Hottest Collab Yet: Dynamite Sweet & Sour Chicken Goes Nationwide With Buldak®
-
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
-
Skyryse Announces Universal, Emergency Autoland Capability Coming to SkyOS™, Bringing Automated Safe Landings to Both Helicopters and Airplanes
-
Bitfarms Expands Leadership Team with Seasoned U.S. Industry Experts to Support HPC/AI Infrastructure Development
-
Panda Express® Brings Back Its Hottest Collab Yet: Dynamite Sweet & Sour Chicken Goes Nationwide With Buldak®
-
Constellation Software Inc. Announces Results for the Fourth Quarter and Year Ended December 31, 2025 and Declares Quarterly Dividend
-
AOI Receives First Volume Order of 1.6T Data Center Transceivers from Major Hyperscale Customer
-
Aecon Utilities expands U.S. electrical utility services capabilities with acquisition of Duna Services and an interest in KNX Utility Services
-
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
-
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
-
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
-
Heineken Holding N.V. reports transactions under its current share buyback programme
-
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinic
-
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
-
ISC Selected to Build and Operate the Future International Registry for Mining, Agriculture and Construction Equipment
-
Nobel Identifies New Mineralized Porphyry Copper System, Cuprita Project, Chile
-
PyroGenesis Announces $1 Million Non-Brokered Private Placement
-
Tilray Brands Acquires BrewDog Australia, Establishing Strategic Base to Accelerate Global Beverage and Consumer Products Growth Across the Asia-Pacific Region
-
B2BROKER and Centroid Strengthen Collaboration to Enhance B2TRADER Liquidity and Risk Capabilities
-
Siris Agrees to Acquire a Majority Stake in TAKKION from Apollo Funds
-
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
-
Zefiro Founder Updates Shareholders on British Columbia Securities Commission Ruling Ahead of Shareholder Vote
